Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests


[Russian Foreign Minister: Russia's Patience Is Not Without Limits] Russian Foreign Minister Sergey Lavrov, In A Media Interview On February 5, Addressed Russia's Previous Goodwill Gestures, Including The Reneging Of The 2025 Energy Truce Agreement With Ukraine. Lavrov Stated That Russia's Patience Is Not Without Limits, And That Russia Always Carefully Weighs Its Options Before Taking Any Action
(US Stocks) The Philadelphia Gold And Silver Index Closed Down 6.25% At 372.66 Points. (Global Session) The NYSE Arca Gold Miners Index Fell 6.03% To 2660.11 Points. (US Stocks) The Materials Index Closed Down 3.87%, And The Metals & Mining Index Closed Down 2.95%
Spot Gold Fell 4.0% To $4,763.2 Per Ounce. New York Gold Fell 3.0% To $4,793 Per Ounce. New York Silver Fell 15.5% To $71.12 Per Ounce. Spot Silver Fell 18.5% To $71.67 Per Ounce. The Commodity Currency Australian Dollar Fell 1.0% Against The US Dollar To 0.6927
Securities And Exchange Commission (SEC) Chairman Atkins Will Appear Before The Senate On February 12
The Federal Reserve's Discount Window Lending Balance Was $4.52 Billion In The Week Ending February 4, Unchanged From The Previous Week
Argentina End-2026 Inflation Seen At 22.4%, Up 2.3 Percentage Points From Prior Forecast, In Central Bank Market Expectations Survey
Argentina End-2026 GDP Growth Seen At 3.2%,Down 0.3 Percentage Points From Prior Forecast, In Central Bank Market Expectations Survey
Toronto Stock Index .GSPTSE Unofficially Closes Down 576.95 Points, Or 1.77 Percent, At 31994.60
The Nasdaq Golden Dragon China Index Closed Up 0.8% Initially. Among Popular Chinese Concept Stocks, Dingdong Maicai Closed Down 15%, Canadian Solar Fell 8.4%, Alibaba And New Oriental Fell 1%, While Xiaomi, Li Auto, And Meituan Rose Over 2%, WeRide Rose 3.6%, Yum China Rose 4.6%, And NIO Rose 6%. In The ETF Market, Ashes Fell 1.7%, Ashr Fell 0.8%, Cqqq Fell 0.8%, And Kweb Fell 0.1%
On Thursday (February 5), The Bloomberg Electric Vehicle Price Return Index Fell 1.88% To 3467.18 Points In Late Trading. It Briefly Rose At 08:17 Beijing Time Before Continuing Its Decline. Among Its Components, Volvo Cars (European Shares) Closed Down 22.53%, Aurora Innovation Shares Fell 9.7%, Plug Power Systems Fell 9%, Mp Materials Fell 7.3%, RoboSense H Shares Closed Up 2.79%, Ranking Fifth, Xiaomi Group H Shares Closed Up 2.83%, WeRide Rose 3.5%, Horizon Robotics H Shares Closed Up 3.64%, And Panasonic Corporation Closed Up 8.41%
Argentina's Merval Index Closed Down 2.65% At 2.936 Million Points, Fluctuating At Low Levels For More Than Half Of The Trading Session
Chicago Soybean Futures Rose About 1.7%, And Soybean Meal Futures Rose More Than 2.2%. At The Close Of Trading In New York On Thursday (February 5), The Bloomberg Grains Index Rose 1.57% To 29.8095 Points. CBOT Corn Futures Rose 1.34%, And CBOT Wheat Futures Rose 1.57%. CBOT Soybean Futures Rose 1.69% To $11.1075 Per Bushel, Soybean Meal Futures Rose 2.26%, And Soybean Oil Futures Were Roughly Unchanged
The US Dollar Index Rose More Than 0.2% In Late New York Trading On Thursday (February 5), With The ICE Dollar Index Rising 0.24% To 97.849, Trading Between 97.607 And 97.915. The Bloomberg Dollar Index Rose 0.20% To 1194.03, Trading Between 1191.07 And 1194.76

Italy IHS Markit Construction PMI (Jan)A:--
F: --
P: --
Euro Zone IHS Markit Construction PMI (Jan)A:--
F: --
P: --
Germany Construction PMI (SA) (Jan)A:--
F: --
P: --
Italy Retail Sales MoM (SA) (Dec)A:--
F: --
P: --
U.K. Markit/CIPS Construction PMI (Jan)A:--
F: --
P: --
France 10-Year OAT Auction Avg. YieldA:--
F: --
P: --
Euro Zone Retail Sales YoY (Dec)A:--
F: --
Euro Zone Retail Sales MoM (Dec)A:--
F: --
U.K. BOE MPC Vote Cut (Feb)A:--
F: --
P: --
U.K. BOE MPC Vote Hike (Feb)A:--
F: --
P: --
U.K. BOE MPC Vote Unchanged (Feb)A:--
F: --
P: --
U.K. Benchmark Interest RateA:--
F: --
P: --
MPC Rate Statement
U.S. Challenger Job Cuts (Jan)A:--
F: --
P: --
U.S. Challenger Job Cuts MoM (Jan)A:--
F: --
P: --
U.S. Challenger Job Cuts YoY (Jan)A:--
F: --
P: --
Bank of England Governor Bailey held a press conference on monetary policy.
Euro Zone ECB Marginal Lending RateA:--
F: --
P: --
Euro Zone ECB Deposit RateA:--
F: --
P: --
Euro Zone ECB Main Refinancing RateA:--
F: --
P: --
ECB Monetary Policy Statement
U.S. Weekly Initial Jobless Claims (SA)A:--
F: --
P: --
U.S. Initial Jobless Claims 4-Week Avg. (SA)A:--
F: --
P: --
U.S. Weekly Continued Jobless Claims (SA)A:--
F: --
ECB Press Conference
U.S. JOLTS Job Openings (SA) (Dec)A:--
F: --
U.S. EIA Weekly Natural Gas Stocks ChangeA:--
F: --
P: --
BOC Gov Macklem Speaks
Mexico Policy Interest RateA:--
F: --
P: --
U.S. Weekly Treasuries Held by Foreign Central BanksA:--
F: --
P: --
Reserve Bank of Australia Governor Bullock testified before Parliament.
Japan Foreign Exchange Reserves (Jan)--
F: --
P: --
India Benchmark Interest Rate--
F: --
P: --
India Cash Reserve Ratio--
F: --
P: --
India Repo Rate--
F: --
P: --
India Reverse Repo Rate--
F: --
P: --
Japan Leading Indicators Prelim (Dec)--
F: --
P: --
Germany Industrial Output MoM (SA) (Dec)--
F: --
P: --
Germany Exports MoM (SA) (Dec)--
F: --
P: --
U.K. Halifax House Price Index YoY (SA) (Jan)--
F: --
P: --
U.K. Halifax House Price Index MoM (SA) (Jan)--
F: --
P: --
France Trade Balance (SA) (Dec)--
F: --
P: --
Canada Leading Index MoM (Jan)--
F: --
P: --
India Deposit Gowth YoY--
F: --
P: --
Canada Employment (SA) (Jan)--
F: --
Canada Full-time Employment (SA) (Jan)--
F: --
Canada Part-Time Employment (SA) (Jan)--
F: --
Canada Unemployment Rate (SA) (Jan)--
F: --
P: --
Canada Labor Force Participation Rate (SA) (Jan)--
F: --
P: --
Due to the previous government shutdown, the release date of the US January non-farm payroll report has been changed to February 11.
Canada Ivey PMI (Not SA) (Jan)--
F: --
P: --
Canada Ivey PMI (SA) (Jan)--
F: --
P: --
U.S. 5-10 Year-Ahead Inflation Expectations (Feb)--
F: --
P: --
U.S. UMich Consumer Sentiment Index Prelim (Feb)--
F: --
P: --
U.S. UMich 1-Year-Ahead Inflation Expectations Prelim (Feb)--
F: --
P: --
U.S. UMich 5-Year-Ahead Inflation Expectations Prelim YoY (Feb)--
F: --
P: --
U.S. UMich Current Economic Conditions Index Prelim (Feb)--
F: --
P: --
U.S. UMich Consumer Expectations Index Prelim (Feb)--
F: --
P: --
China, Mainland Foreign Exchange Reserves (Jan)--
F: --
P: --
Russia Retail Sales YoY (Dec)--
F: --
P: --
Russia Unemployment Rate (Dec)--
F: --
P: --














































No matching data
View All

No data
China's biopharmaceutical companies are set for rapid earnings growth from 2026, driven by greater globalization and improving operating efficiency, UOB Kay Hian analysts Carol Dou and Sunny Chen say in a note. They expect margin expansion from drug innovators, supported by their licensing income, better cost structures and overseas growth, and they like BeOne Medicines, Innovent and Hansoh Pharma in that segment. Contract research, development and manufacturing organizations should see stronger earnings and rising demand in 2026, with WuXi AppTec and WuXi Bio favored. Internet healthcare leaders with stable business models and AI adoption are also expected to deliver solid compound annual earnings growth through 2027, with Ali Health preferred for its synergies with Alibaba and attractive valuation. UOB KH maintains an overweight call on China's healthcare sector. (jason.chau@wsj.com)
BeOne Medicines could deliver sustainable revenue growth through new product launches, UOB Kay Hian analysts Carol Dou and Sunny Chen say in a note. They view the company's new $5.1 billion-$5.3 billion revenue target as highly achievable and expect further improvements in operating efficiency and cash generation by leveraging its global operating platform. The analysts say BeOne's anticancer treatment Brukinsa will likely continue to lift global sales in coming years, supported by its best-in-class profile and expanding market penetration. "BeOne Medicines has entered a new era of development with positive profit and free cash flow from 2025 onwards," they say, citing a more diversified revenue mix and improving margins. UOB Kay Hian has a buy rating on the stock with a HK$252.00 target. Its H-shares last traded at HK$193.10. (jason.chau@wsj.com)
By Adriano Marchese
BeOne Medicines said U.S. regulators have agreed to fast-track the review its new drug to treat adults with mantle cell lymphoma, a form of blood cancer.
The cancer treatment company said Wednesday that the Food and Drug Administration has accepted and granted priority review to a new drug application for sonrotoclax, a new BCL2 inhibitor intended to treat adult patients with relapsed or refractory mantle cell lymphoma.
Mantle cell lymphoma is a rare, fast-growing blood cancer that starts in the lymph nodes.
The decision was based on data from a phase 1/2 study which enrolled 125 adult patients with the specific type of blood cancer who had received prior treatment. The trial results found that sonorotoclax achieved its primary endpoints of overall response rate, and also showed promising results across several secondary efficacy endpoints, it said.
"Sonrotoclax is advancing with remarkable speed, from breakthrough therapy designation to priority review, all within a short window," Global Head of Research and Development at BeOne, Lai Wang, said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(18:01 GMT) BeOne Medicines Price Target Announced at $400.00/Share by Truist Securities
(18:01 GMT) BeOne Medicines Price Target Announced at $400.00/Share by Truist Securities
(15:39 GMT) BeOne Medicines Price Target Raised to $408.00/Share From $395.00 by RBC Capital
A unique global infrastructure and rapid R&D have driven strong financial growth and a broad pipeline, with leading CLL therapies and innovative solid tumor programs advancing. Strategic investments and disciplined capital allocation support over 20 phase III trials next year.
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features
Log In
Sign Up